{
  "paper_id": "7cd5321d8b9deb046502c0f1ab1581e7200bc378",
  "metadata": {
    "title": "DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T- Cell Responses after rAd5 Boost in a Randomized Clinical Trial",
    "coda_data_split": "train",
    "coda_paper_id": 10058,
    "coda_has_expert_labels": false,
    "subset": "comm_use_subset"
  },
  "abstract": [
    {
      "original_text": "Background: DNA vaccine immunogenicity has been limited by inefficient delivery. Needle-free delivery of DNA using a CO 2 -powered BiojectorH device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity.",
      "sentences": [
        [
          {
            "segment_text": "Background : DNA vaccine immunogenicity has been limited by inefficient delivery .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "Needle-free delivery of DNA using a CO 2 - powered BiojectorH device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity .",
            "crowd_label": "background"
          }
        ]
      ]
    },
    {
      "original_text": "Methods: Forty adults, 18-50 years, were randomly assigned to intramuscular (IM) vaccinations with DNA vaccine, VRC-HIVDNA016-00-VP, (weeks 0, 4, 8) by BiojectorH 2000 TM or needle and syringe (N/S) and boosted IM at week 24 with VRC-HIVADV014-00-VP (rAd5) with N/S at 10 10 or 10 11 particle units (PU). Equal numbers per assigned schedule had low (#500) or high (.500) reciprocal titers of preexisting Ad5 neutralizing antibody.",
      "sentences": [
        [
          {
            "segment_text": "Methods : Forty adults , 18-50 years ,",
            "crowd_label": "method"
          },
          {
            "segment_text": "were randomly assigned to intramuscular ( IM ) vaccinations with DNA vaccine ,",
            "crowd_label": "method"
          },
          {
            "segment_text": "VRC-HIVDNA016-00-VP , ( weeks 0 , 4 , 8 ) by BiojectorH 2000 TM or needle and syringe ( N/S ) and boosted IM at week 24 with VRC-HIVADV014-00-VP ( rAd5 ) with N/S at 10 10 or 10 11 particle units ( PU ) .",
            "crowd_label": "method"
          }
        ],
        [
          {
            "segment_text": "Equal numbers per assigned schedule had low ( # 500 ) or high ( .500 ) reciprocal titers of preexisting Ad5 neutralizing antibody .",
            "crowd_label": "method"
          }
        ]
      ]
    },
    {
      "original_text": "Results: 120 DNA and 39 rAd5 injections were given; 36 subjects completed follow-up research sample collections. IFN-c ELISpot response rates were 17/19 (89%) for BiojectorH and 13/17 (76%) for N/S delivery at Week 28 (4 weeks post rAd5 boost). The magnitude of ELISpot response was about 3-fold higher in BiojectorH compared to N/S groups. Similar effects on response rates and magnitude were observed for CD8+, but not CD4+ T-cell responses by ICS. Env-specific antibody responses were about 10-fold higher in Biojector-primed subjects.",
      "sentences": [
        [
          {
            "segment_text": "Results : 120 DNA and 39 rAd5 injections were given ; 36 subjects completed follow-up research sample collections .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "IFN-c ELISpot response rates were 17/19 ( 89 % ) for BiojectorH and 13/17 ( 76 % ) for N/S delivery at Week 28 ( 4 weeks post rAd5 boost ) .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "The magnitude of ELISpot response was about 3-fold higher in BiojectorH compared to N/S groups .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "Similar effects on response rates and magnitude were observed for CD8 + ,",
            "crowd_label": "finding"
          },
          {
            "segment_text": "but not CD4 + T-cell responses by ICS .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "Env-specific antibody responses were about 10-fold higher in Biojector-primed subjects .",
            "crowd_label": "finding"
          }
        ]
      ]
    },
    {
      "original_text": "Conclusions: DNA vaccination by BiojectorH was well-tolerated and compared to needle injection, primed for greater IFN-c ELISpot, CD8+ T-cell, and antibody responses after rAd5 boosting.",
      "sentences": [
        [
          {
            "segment_text": "Conclusions : DNA vaccination by BiojectorH was well-tolerated and compared to needle injection ,",
            "crowd_label": "finding"
          },
          {
            "segment_text": "primed for greater IFN-c ELISpot ,",
            "crowd_label": "finding"
          },
          {
            "segment_text": "CD8 + T-cell , and antibody responses after rAd5 boosting .",
            "crowd_label": "finding"
          }
        ]
      ]
    }
  ],
  "abstract_stats": {
    "paragraph_num": "4",
    "sentence_num": "10",
    "segment_num": "15",
    "token_num": "261"
  }
}